oncodaily - Purdue Institute for Cancer Research shared a post on LinkedIn: “Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, […]
AI Summary: Purdue researchers unveiled an automated mass‑spectrometry platform that compresses key steps of small‑molecule drug discovery into a matter of hours, promising faster lead identification and screening. The system couples high‑throughput chemistry with rapid readouts to accelerate iteration cycles, potentially shrinking timelines and costs for early oncology drug development — welcome news for impatient scientists.
Dendritic cells build tumour immune hubs sustaining anti-tumour responses / 1 month
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 6 months
Merck and Moderna report positive phase‑3 melanoma vaccine results / 4 wks
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 4 wks
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 5 wks
Mass release of next‑generation tumor organoids accelerates research / 5 wks
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 7 wks
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.